Research programme: calreticulin - Antigenics

Drug Profile

Research programme: calreticulin - Antigenics

Latest Information Update: 20 Nov 2007

Price : $50

At a glance

  • Originator Duke University Medical Center
  • Developer Antigenics
  • Class Calcium binding proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Aug 2006 This programme is still in active development
  • 02 Jul 2002 This compound is still in active development
  • 20 Mar 2000 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top